Mustang Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2019

The following table summarizes stock option activities for the three months ended March 31, 2019:

	Stock Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)
Outstanding at December 31, 2018		1,241,675	$	5.73		8.31
Options granted		-		-
Outstanding at March 31, 2019		1,241,675		5.73		8.06
Options vested and exercisable at March 31, 2019		271,615	$	5.73		8.06

The following table summarizes stock-based compensation expense for the three months ended March 31, 2019 and 2018 (in thousands).

	For the three months ended March 31,
	2019		2018
General and administrative	$	336	$	705
Research and development		96		1,290
Total stock-based compensation expense	$	432	$	1,995

A summary of warrant activities for three months ended March 31, 2019 is presented below:

	Warrants			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)
Outstanding as of December 31, 2018		5,210,698		$	8.32		3.10
Granted		288,184			3.47		10.00
Exercised		(57,867	)		-		-
Outstanding as of March 31, 2019		5,441,015		$	8.15		3.17

The following table summarizes restricted stock award activities for the three months ended March 31, 2019:

	Number of Shares		Weighted Average Grant Date Fair Value
Nonvested at December 31, 2018		502,636	$	5.76
Granted		-		-
Nonvested at March 31, 2019		502,636	$	5.76

The following table summarizes restricted stock units activities for the three months ended March 31, 2019:

	Number of Units			Weighted Average Grant Date Fair Value
Nonvested at December 31, 2018		1,032,084		$	7.77
Granted		-			-
Forfeited		(201,250	)		8.03
Vested		(76,000	)		10.81
Nonvested at March 31, 2019		754,834		$	7.39